AMN Healthcare Services enters the week with an unusual combination: shorts rebuilding at a clip not seen in months, options positioning at its most defensive in over a year, and the stock itself trading above the consensus analyst price target.
The short interest picture is the clearest signal of renewed skepticism. Bears have added meaningfully — SI has climbed roughly 33% over the past month to reach 8.1% of the free float, with the week-on-week move adding another 3.5%. That takes the short position back toward the top of its recent range. The borrow market, though, shows no stress: availability is at 735% — meaning roughly seven shares remain available for every one already borrowed — and cost to borrow is a negligible 0.44%, down 15% on the week. Availability has actually tightened sharply from early May levels above 2,000%, tracking the rise in short interest, but at 735% the lending pool remains far from strained. Shorts are rebuilding, but they're doing so cheaply and without friction.
Options positioning adds a different layer of caution. Put demand has climbed well above its recent norm: the put/call ratio hit 1.07 on Tuesday, more than 2.5 standard deviations above its 20-day average of 0.85, the most defensive options reading for AMN in over a year outside of the brief spike to 1.41 last summer. This is two weeks running that the PCR has been elevated. That's not noise — it's options traders buying protection, likely ahead of the August 6 earnings date.
The Street's reaction to AMN's last print complicates the bearish setup. The stock jumped 38% on May 7 earnings day and held most of that gain, rising 44% over the following five days. Analysts lifted targets across the board in the days after — UBS moved from $19.50 to $32.00, BMO raised to $26.00, Baird and Truist also nudged higher. The result is a consensus that still looks flat-footed: the mean target of around $28 sits below Tuesday's close of $31.24, suggesting analysts have yet to fully re-rate after the May surge. Citizens reiterated Market Outperform with a $36 target as recently as June 23 — the only current upside target on the board. That lone bullish target now represents the clearest upside anchor, while the rest of the Street remains cautious on a name whose price has now run past most of their published numbers.
Fundamental tension remains the core debate. The bull case rests on AMN's history of beating estimates — revenue has come in above consensus for several consecutive quarters, with EBITDA surprises averaging 12% — and a forward EPS growth profile that justifies some re-rating. The bear case points to structural revenue pressure: nurse and allied segment revenues fell 9% year-on-year last quarter, physician solutions dropped 14%, and vendor management system revenue plunged 31%. Operating margins have compressed. The stock's P/E has expanded to around 16x as the price has risen, with EV/EBITDA near 8.2x — multiples that carry execution risk if Q3 guidance disappoints.
With next earnings pencilled in for August 6, the tension between rebuilt short positions, elevated put demand, and a stock trading above most analyst targets is the dynamic worth monitoring as that date approaches.
See the live data behind this article on ORTEX.
Open AMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
